/PRNewswire/ New Directions Behavioral Health ("New Directions"), a provider of comprehensive behavioral health solutions, today announced its acquisition.
Tridiuum and NOCD Partner to Diagnose OCD Patients Faster and Accelerate Access to Clinically Proven Treatment
Integration of solutions from top behavioral health company and leading specialty provider will facilitate rapid, data-driven referrals and empower patients to receive the right treatment in less time
News provided by
Share this article
Tridiuum, the nation s premier provider of digital behavioral health solutions, and
NOCD, the leading provider for the treatment of obsessive-compulsive disorder (OCD), today announced a first-of-its kind partnership to support individuals suffering from OCD. The new partnership focuses on identifying more patients with OCD to diagnose them correctly faster and with less effort. The integrated approach will guide patients to NOCD s therapy, which is clinically proven to reduce impairment and distress from OCD symptoms in 90 percent of patients.
According to a Kaiser Family Foundation
poll, 53 percent of U.S. adults reported that their mental health had been negatively impacted by the virus.
Census Bureau data in December revealed that U.S. mental health problems have reached all-time highs, with almost half of Americans now showing signs of clinical anxiety or depression.
The CDC also reported that U.S. hospitals saw a 31% increase in the proportion of mental health emergency visits for adolescents ages 12 to 17 from April to October 2020.
Access to mental health services is a growing problem: 54% of behavioral health organizations reported they have had to close programs while 65% have had to cancel, reschedule, or turn away patients in need. At the same time, demand for mental health services is continuing to rise.
(2)
PHILADELPHIA, PA / ACCESSWIRE / December 10, 2020 / Tridiuum, the nation s premier provider of digital behavioral health solutions, today announced it has been selected for a first-of-its-kind behavioral health pilot with Fresenius Medical Care North America (FMCNA), the nation s leading provider of kidney care products and services. The pilot, which will begin with dialysis centers in the North Georgia area, will integrate the Tridiuum ONE platform into the company s clinical workflow for early identification of patients behavioral health issues.
Studies show that behavioral health conditions, including depression and anxiety disorders, are prevalent in patients with chronic kidney disease (CKD). These conditions often impact patients overall quality of life and can lead to longer hospitalizations and higher mortality. Undiagnosed behavioral conditions can directly affect a patient s adherence to lifesaving treatment and medication regimens.